Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q4 2022 Earnings Call Transcript
Operator: Good morning, everyone. My name is Todd, and I'll be your conference operator.
Eagle Pharmaceuticals Inc. (EGRX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Adage Capital Management Phill Gross And Robert Atchinson | 400,000 | $11,692,000 | +60% | 0.02% |
| 2. | AQR Capital Management Cliff Asness | 135,315 | $3,955,257 | +42% | 0% |
| 3. | Tang Capital Management Kevin C. Tang | 118,857 | $3,474,190 | 0.5% | |
| 4. | Citadel Investment Group Ken Griffin | 113,701 | $3,323,480 | -39% | 0% |
| 5. | 60,100 | $1,756,723 | -56% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $55.45 | 350 | Officer | 700 | 2017-08-16 | Filing | |
| $50.09 | 1,584 | Director | 971,000 | 2017-08-09 | Filing | |
| $49.21 | 15,206 | Director | 969,416 | 2017-08-09 | Filing | |
| $48.06 | 3,610 | Director | 954,210 | 2017-08-09 | Filing | |
| $71.49 | 350 | Officer | 350 | 2017-06-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $30.99 | 6,800 | Director | 22,600 | 2022-09-06 | Filing | |
| $63.57 | 15,437 | Director | 732,777 | 2019-10-25 | Filing | |
| $62.53 | 1,494 | Director | 748,214 | 2019-10-24 | Filing | |
| $62.58 | 200 | Director | 749,708 | 2019-10-23 | Filing | |
| $62.68 | 6,567 | Director | 749,908 | 2019-10-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 1,874,448 | $54,790,116 | 0% | |
| 2. | 1,229,872 | $35,949,061 | 0.02% | |
| 3. | 952,026 | $27,827,720 | 0% | |
| 4. | 763,807 | $22,326,079 | 0% | |
| 5. | 416,177 | $12,164,854 | 0.34% |
News See All
What Made Eagle Pharmaceuticals (EGRX) Stock to Decline in Q3?
Scout Investments, an affiliate of Carillon Tower Advisers, an investment management company, released its “Carillon Scout Small Cap Fund” third quarter 2022 investor letter.
Were Hedge Funds Right About Eagle Pharmaceuticals Inc (EGRX)?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September.
Here's Why Summers Value Partners Exited its Eagle Pharmaceuticals (EGRX) Position
Summers Value Partners, an investment management firm, published its “Summers Value Fund LP” first quarter 2021 investor letter – a copy of which can be downloaded here.
Is EGRX A Good Stock To Buy Now?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Eagle Pharmaceuticals (EGRX) Has Fallen 26% in Last One Year, Underperforms Market
If you are looking for the best ideas for your portfolio you may want to consider some of Del Principe O’Brien Financial Advisors top stock picks.
Eagle Pharmaceuticals (EGRX) Has Fallen 38% in Last One Year, Underperforms Market
If you are looking for the best ideas for your portfolio you may want to consider some of Summers Value Partners top stock picks.
Hedge Funds Are Buying Eagle Pharmaceuticals Inc (EGRX)
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter.
Eagle Pharmaceuticals Inc (EGRX): Are Hedge Funds Right About This Stock?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November.
Do Hedge Funds Love Eagle Pharmaceuticals Inc (EGRX)?
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th.
Billionaire Hedge Funds
